Sodium citrate 4% versus heparin as a lock solution in hemodialysis patients with central venous catheters.
Research article published in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2013)
Abstract
PURPOSE: The effects of heparin versus sodium citrate 4% as a lock solution on catheter-related infections (CRIs), catheter patency, and hospitalizations in long-term hemodialysis patients with central venous catheters (CVCs) were compared. METHODS: Data for patients receiving heparin lock solutions were collected from July 2008 to July 2009. Data on patients receiving sodium citrate 4% lock solution were collected from September 2009 through December 2010. Patients who were receiving the heparin lock solution who continued to have a CVC in September 2009 were transitioned from heparin to sodium citrate catheter 4% lock solution. New patients with CVCs placed after September 2009 received sodium citrate 4% without a period of using heparin lock solution. Pertinent information on patient medical history, bleeding or clotting events, infections, and hospitalization was collected. Data were collected retrospectively for the heparin group and prospectively for the sodium citrate group. RESULTS: Data were collected from 360 patient-months among 60 patients during the heparin treatment period and from 451 patient-months among 58 patients during the sodium citrate period. Thirty-three patients were common to both study groups. There were significantly more CRIs and CRIs per 1000 catheter-days in the heparin than the sodium citrate treatment group. Secondary outcomes of hospitalizations and catheter thrombosis were comparable. CRIs and thrombosis led to significantly more catheter exchanges or removals in the heparin group than the sodium citrate group. CONCLUSION: In patients with long-term hemodialysis catheters, a lock solution of sodium citrate 4% was associated with fewer CRIs and similar effectiveness when compared with heparin 5000 units/mL.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
The effects of heparin versus sodium citrate 4% as a lock solution on catheter-related infections (CRIs), catheter patency, and hospitalizations in long-term hemodialysis patients with central venous catheters (CVCs) were compared. Data for patients receiving heparin lock solutions were collected...
Por qué esto importa para la hirudoterapia
Este estudio comparativo comparó citrato de sodio al 4 % frente a heparina 5.000 U/mL como soluciones de sellado de catéter en pacientes en hemodiálisis de larga duración con catéteres venosos centrales, abarcando 360 y 451 pacientes-mes respectivamente. El citrato de sodio al 4 % se asoció con un número significativamente menor de infecciones relacionadas con el catéter y tasas comparables de trombosis del catéter y hospitalizaciones en relación con la heparina. Para el ámbito de ASH, este estudio toca las estrategias de sellado anticoagulante relevantes para mantener la permeabilidad del catéter, un tema periférico. Sin embargo, el estudio no tiene conexión con las sanguijuelas, la hirudoterapia ni el secretoma de la sanguijuela; cualquier relevancia se limita al contexto amplio del uso de anticoagulantes en la práctica clínica, y no se discuten agentes ni conceptos derivados de sanguijuelas.
Citación
Sodium citrate 4% versus heparin as a lock solution in hemodialysis patients with central venous catheters.
Yon et al. · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026